home All News open_in_new Full Article

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and 24% sequentially SUNOSI® 2Q 2025 net product revenue of $30.0 million, representing growth of 35% year-over-year and 19% sequentially SYMBRAVO® launched June 10th, […]


today 1 week ago attach_file Economics

attach_file Culture
attach_file Culture
attach_file Culture
attach_file Other
attach_file Culture
attach_file Other
attach_file Culture
attach_file Economics
attach_file Economics
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Economics
attach_file Society
attach_file Other
attach_file Culture
attach_file Economics
attach_file Culture
attach_file Culture


ID: 3368917442
Add Watch Country

arrow_drop_down